SAN DIEGO, March 31, 2020 (GLOBE NEWSWIRE) -- Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in Akcea Therapeutics, Inc. (NASDAQ: AKCA) shares.
Investors, who purchased shares of Akcea Therapeutics, Inc. (NASDAQ: AKCA), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The plaintiff alleges that certain directors of Akcea Therapeutics, Inc. breached their fiduciary duties. More specifically, the plaintiff alleges that the defendants allowed that the controlling stockholder of Akcea Therapeutics, Inc. forced Akcea Therapeutics, Inc. to bear nearly all of the risk associated with attempting to commercialize its inotersen drug TegSedi, an antisense drug for the treatment of ATTR amyloidosis (“ATTR”), while securing hundred of millions of dollars from Akcea Therapeutics, Inc. in upfront payments retained a majority of the potentially billions of dollars of upside if the drug achieves commercial success.
Those who purchased Akcea Therapeutics, Inc. (NASDAQ: AKCA) shares should contact the Shareholders Foundation, Inc.
CONTACT:
Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
mail@shareholdersfoundation.com
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.